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To Edit or Not to Edit?-

Regulating CRISPR
Transnationally
ABSTRACT

After Chinese scientistDr. He Jiankui'sannouncement that he had
successfully edited the human genome using a new technology
called CRISPR/Cas-9, Dr. He forced the world to address the
ethical dilemmas introduced by gene-editing technologies. Born
out of a historicaltraditionof human "improvement,"gene-editing

technologies like CRISPR/Cas-9 modify human genes down to
DNA molecules. CRISPR can prevent and cure genetic diseases
that have previously had no cure, but problems arise when
CRISPR's use expands to enhancements or to modifications that
would change the human genome permanently. Given CRISPR's
potentialprofound impact, this Note analyzes how international
bodies like the United Nations and countries like the United

States, the United Kingdom, and Japan have attempted to
regulate gene-editing technologies such that beneficial, individual
modifications can flourish and rash, permanent modifications are
avoided. This Note recommends the creation of the International
Gene-Editing Ethics Commission, which

would promulgate

publicly approved ethical standards for gene editing while also
providingmember countrieswith access to publication in scientific
journals, funding, and an internationaldatabase.
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WHY WE NEED BETTER CRISPR REGULATIONS

In the fall of 2018, Chinese scientist Dr. He Jiankui announced
that he edited the genes of human embryonic cells for the first time in
history, and that the mother had given birth to the babies already.' Dr.
He inserted CRISPR/Cas-9 (Clustered Regularly Interspaced Short
Palindromic Repeats/CRISPR-associated protein 9) into germline cells,
in order to naturally immunize the babies to human immunodeficiency

virus (HIV). 2 Once the embryonic cells received the vector, they were
then placed in the mother via in vitro fertilization. 3 Nine months later,
Dr. He announced his feat, propelling the global community into the
germline-editing era without its permission. 4
In 2015, before this groundbreaking announcement, the scientific
communities of the United States, the United Kingdom, and China

decided to meet for the first International Summit on Human Gene
Editing in Washington, DC to hash out guiding principles for gene-

editing

technologies. 5

After

several

conferences

and

lengthy

See David Cyranoski, The CRISPR-Baby Scandal: What's Next for Human
1.
Gene-Editing, NATURE (Feb. 26, 2019), https://www.nature.com/articles/d41586-01900673-1 [https://perma.cc/AA4Q-AR9T] (archived Sept. 6, 2020).
See Jing-ru Li, Simon Walker, Jing-bao Nie & Xin-quing Zhang, Experiments
2.
that Led to the First Gene-Edited Babies: The Ethical Failings and the Urgent Need for
Better Governance, 20 J. ZHEJIANG U. BIOMED. & BIOTECH. 32, 33 (2019).
3.
See Cyranoski, supranote 1.
4.
See id.
See David Baltimore, Frangois Baylis, Paul Berg, George Daley, Jennifer
5.
Doudna, Paul Lander, Robin Lovell-Badge, Pilar Ossorio, Duanqing Pei, Adrian
Thrasher, Ernst-Ludwig Winnacker & Qi Zhou, On Human Gene Editing: International
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discussions

among

the

lawyers,

scientific

leaders,

and

other

international scholars, the Summit released its first statement on the
issue of gene editing in clinical trials.6 The Summit affirmed the need
for meticulous preclinical research, approved clinical trials involving
the editing of somatic cells under the existing regulatory framework,
and firmly prohibited gene editing on germline cells until further
notice.7 The Committee emphasized that it was crucial to continue

meeting to readdress the global scientific standards it had been
charged with overseeing. 8
The second International Summit met in Hong Kong in November
of 2018 with quite a different tone. 9 At this summit, Dr. He announced
his clinical trial and the birth of the twins.1 0 While the Committee did
not approve of Dr. He's experiment and he received three years in
prison for it, the Committee understood that the gene editing of

germline cells was a reality that needed to be addressed quickly and
globally."
By way of background, scientists divide gene editing into two
broad categories: somatic cell editing and germline cell editing.' 2

Somatic, literally meaning "of the body," refers to the living cells of
humans, whereas germline cells are reproductive cells.' 3 Modifying the
somatic cells of a human corrects an inheritable gene in that person
only; the modifications will not be inheritable because those cells will
not be used in reproduction.' 4 Germline cell modification, meaning

Summit

Statement,

NAT'L

ACAD.

SCI.,

ENG'G,

AND

MED.,

(Dec.

3,

2015),

[ht
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a
tps://perma.cc/GS6S-SZH4] (archived Sept. 6, 2020).
See id.
6.
7.
See id.
See id.; see generally NAT'L ACADS. OF SCIS., ENG'G, AND MED., HUMAN
8.
GENOME EDITING: SCIENCE, ETHICS, AND GOvERNANCE (2017) (serving as the definitive

report following the International Summit's statement).
9.
See David Baltimore, Alta Charo, George Daley, Jennifer Doudna, Kazuto
Kato, Jin-Soo Kim, Robin Lovell-Badge, Jennifer Merchant, Indira Nath, Duanqing Pei,
Matthew Porteus, John Skehel, Patrick Tam & Xiaomei Zhai, On Human Gene Editing
II: InternationalSummit Statement, NAT'L ACAD. ScI., ENG'G, AND MED. (Nov. 28, 2018),
https://www.nationalacademies.org/news/2018/11/statement-by-the-organizing-commit
[https://perma.cc/K
tee-of-the-second-international-summit-on-human-genome-editing
NS3-RJF4] (archived Sept. 6, 2020); Sui-Lee Wee, Chinese Scientist Who Genetically
Edited Babies Gets 3 Years in Prison, N.Y. TIMES (Dec. 30, 2019),
https://www.nytimes.com/2019/12/30/business/china-scientist-genetic-baby-prison.html
[https://perma.c/EYA6-93UJX (archived Nov. 10, 2020).
10.
See id.
11.
See id.
12.
See id.
13.

See

Somatic, MERRIAM-WEBSTER DICTIONARY (2019); Giulia Cavaliere,

Background Paper:The Ethics of Human Genome Editing, WORLD HEALTH ORG. 1 (Mar.
18, 2019), https://www.who.int/ethics/topics/human-genome-editing/WHO-Commission
ed-Ethics-paper-Marchl9.pdf [https://perma.cc/NUB5-U3GC] (archived Sept. 6, 2020).
14.
See Cavaliere, supranote 13, at 2.
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modifications of the cells used to reproduce, will affect the human
15
genome permanently because changes in those cells are inheritable.
Different ethical issues arise with each type of gene editing.
Ethical questions arise in the somatic cell editing context when
deciding which purposes are acceptable for justifying its use. Germline

16
cell editing can raise questions about designer babies and consent.
Yet some bioethical concerns underpin both types of editing-those
scientific
regulation, and
questions such as accessibility,

responsibility. 17 This Note will primarily focus on questions
surrounding the regulation of clinical somatic cell editing, though
much of its discussion could apply to germline editing in the future.

Because CRISPR's minimal off-target effects, cheaper use, and
precision distinguish it from other gene-editing technologies, like zinc-

finger nucleases and TALENs (transcriptor activator-like effector
18
nucleases), gene editing is more accessible than ever before.
Additionally, considering the existing global and national frameworks
failed to prevent a scientist from using CRISPR to permanently alter

the human genome, the need for an international legal solution is clear.
Beyond the international summits discussed above, international
legal communities are working together to begin addressing the issues
surrounding gene editing. Because the scientific community is truly a
global one, international legal communities aim to harmonize

regulation of technological advancement. 19 In 1998, the United
Nations published the Universal Declaration of the Human Genome
and Human Rights. Among other things, it emphasized the dignity of

the human genome; the rights of patients; the goals of promoting
respectful, cooperative, and innovative research; the need for national
regulations of gene-editing technologies; and the need for international
20
solidarity on each of these topics. In 2015, the International Summit
on Human Gene Editing, referenced above, prompted a conversation
between the world's scientific scholars and bioethicists concerning the

See id.
15.
For example, parents who decide to use gene-editing technology to ensure
16.
their baby has blue eyes cannot obtain the consent of the baby. See Tara R. Melillo, Note,
Gene Editing and the Rise of DesignerBabies, VAND. J. TRANSNAT'L. L. 757, 771 (2017).
See, e.g., Siddhartha Mukherjee, Ethical Challenges Accompany Genetic
17.
'Fixes',

VAND.

CHANCELLOR'S

LECTURE

SERIES

(Nov.

2,

2018),

https://news.vanderbilt.edu/2018/ 11/02/chancellors-lecturer-ethical-challenges-accomp
any-genetic-fixes/ [https://perma.cc/8EQ4-GB3L (archived Sept. 6, 2020) (noting that
with technologies that can sequence the human genome and even alter it, companies like
23andMe now have access to millions of people's genetic data with very little guidance
on how to treat this information).
See id.; Cavaliere, supra note 13, at 1.
18.
See R. Alta Charo, The Legal and Regulatory Context for Human Gene
19.
Editing, 32 no. 3 ISSUES IN SCI. & TECH. (2016), https://issues.org/the-legal-and(archived
[https://perma.cc/QDN5-57NS]
regulatory-context-for-human-gene-editing/
Sept. 6, 2020).
20.
See G.A. Res. 53/152, Declaration on the Human Genome and Human Rights
(Dec. 9, 1998).
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use of gene editing in clinical trials. 21 The World Health Organization's
Expert Advisory Committee on Developing Global Standards for

Governance and Oversight of Human Genome Editing met for the first
time in 2019 to discuss plans for the next twelve to eighteen months. 2 2
But Dr. He's permanent alteration of the human genome calls the
practicality and effectiveness of such vague international guidance into
question.2 3
On a national scale, countries like the United States, the United
Kingdom, and Japan have hashed out the details of regulating clinical
somatic cell editing in their respective countries. 24 Each of these

countries attempt to balance retaining pre- and post-market control of
gene-editing technologies with too strict regulations that may stifle
scientific innovation altogether.2 5 The United States established a
complex regulatory framework for policing mainly pre-market geneediting technologies via guidelines for research funding.2 6 While this
has appeared to effectively control research and pre-market practices,
these regulations are relatively weak once an item is in the market.

The regulations fail to control who can use the technology, in what
conditions they can use the technology, and how often they may use
the technology.27 The United Kingdom regulates both the pre-market

and post-market research and treatment of gene-editing technologies
at

length,

while

still

complying

with

the

European

Union's

framework. 28 Finally, in Japan, the regulations of gene editing classify
each product by degree of risk and apply a regulatory process based on
that

determination.29

Though

Japan's

science,

technology,

and

21.
See Baltimore, Baylis, Berg, Daley, Doudna, Lander, Lovell-Badge, Ossorio,
Pei, Thrasher, Winnacker & Zhou, supra note 5.
See World Health Organization [WHO], Expert Advisory Committee on
22.
Developing Global Standardsfor Governanceand Oversight of Human Genome Editing,
WORLD

HEALTH

ORG.

(2019),

https://www.who.int/ethics/topics/human-genome-

editing/WHO-Commissioned-Ethics-paper-Marchl9.pdf [https://perma.cc/ZQ57-GPWF]
(archived Sept. 6, 2020).
23.
See Tsung-Ling Lee, Two Minutes to Midnight-What InternationalLaw
Can Do About Genome Editing, 14 ASIAN J. WTO & INT'L HEALTH L. & POL'Y 227, 24448 (2019). See generally Li, Walker, Nie & Zhang, supra note 2.
24.
See Charo, supranote 19.
25.
See id.
See id.; Evita V. Grant, FDA Regulation of ClinicalApplications of CRISPR26.
CAS Gene-Editing Technology, 71 FoOD & DRUG L.J. 608, 614-16 (2016). But see
National Institute of Health Office of Science Policy, Recombinant DNA Advisory
Committee

Archives,

NAT'L

INST.

OF

HEALTH

(2019),

https://osp.od.nih.gov/biotechnology/recombinant-dna-advisory-committee/
[https://perma.cc/H858-BN7L] (archived Sept. 6, 2020) (noting that the Recombinant
DNA Advisory Committee has taken a broader focus on recombinant or synthetic nucleic
acid research and renamed itself the Novel and Exception Technology and Research
Advisory Committee, or NExTRAC).
27.
See Charo, supranote 19.
28.
See id.; James Lawford Davies, The Regulation of Gene Editingin the United
Kingdom, 13 ScITECH LAw. 14, 16 (2016).
29.
See Charo, supranote 19.

1 732

VANDERBIL TJOURNAL OF TRANSNA TIONAL

LAW

[VOL. 53:"1727

biotechnology market ranks second-most advanced in the world, the
bureaucratic process through which scientists must venture in order to

receive funding for gene therapy research and clinical trials has
substantially slowed growth in that area.3 0
Even assuming domestic governments are in the best position to

regulate scientific technology, an issue as fundamental and global as
the future of the human genome requires an international, legally
binding solution. 31 Part II details the history of gene editing with
CRISPR and its journey to becoming an accepted tool in somatic cell
clinical trials. Part III will analyze the existing international and

national frameworks regulating clinical trials of somatic cell gene
editing in the United States, the United Kingdom, and Japan, with an
eye towards the possibility of germline editing. Finally, Part IV of this
Note will propose the International Gene-Editing Ethics Commission

to create and enforce a binding whistle-blower framework in the global
scientific community. This whistle-blower framework would provide
qualifications to become a member of the commission and standards

for clinical trial approval that emphasize transparency and consensus.
It would then provide a way for scientists to blow the whistle on

questionable experiments, and issue penalties for those who violate
standards.

II. WHAT IS CRISPR AND WHY SHOULD WE REGULATE IT?

Ideas about changing the human race biologically dramatically
pre-date gene-editing technology itself 32 This Part briefly outlines the
historical origins of the ideas that underpin gene editing, explains

what CRISPR actually does, and highlights bioethical concerns
implicated by CRISPR that affect its governance.

See Sunyoung Kim, Zhaohui Peng & Yasufumi Kaneda, Current Status of
30.
Gene Therapy in Asia, 16 MOLECULAR THERAPY 237, 239-40 (2008).
See NAT'L ACADS. OF SCIs., ENG'G., AND MED., supra note 8, at 57 ("As noted
31.
by former FDA Commissioner Robert Califf, '[s]cientific advances do not adhere to
national boundaries and therefore it is critical that we understand the evolving views of
our international counterparts."').
See PHILLIPA LEVINE, EUGENICS: A VERY SHORT
32.

(discussing eugenics as a part of gene editing history).

INTRODUCTION

4 (2017)

1
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A. Origins of Gene EditingIndicate the Need for Regulation
Gene editing originated, at least partially, in eugenics. 33 The

definition of eugenics is subjective-generally, it is the idea that one
can control reproduction in a way that "improves" future generations.
The danger of eugenic thought lies in the decision of what "improves"
a future generation. Gene-editing technologies are inherently eugenic
because a current generation decides what would genetically improve
the next generation. Given this intertwining of gene editing and
eugenics, the following chronological history of gene editing and

eugenics exemplifies the gravity of the need for regulation of geneediting technologies. Gregor Mendel's discovery of inheritable traits
that could not be changed throughout life laid a foundational concept
in the minds of scientists when it was translated in the early twentieth
century: our genes cannot be changed by behavior or environment. 34
Francis Galton aimed to apply Mendel's findings to human
reproduction, and the eugenics movement caught momentum in the

United States.3 5 Even influential leaders like Theodore Roosevelt,
Francis Crick, and Oliver Wendell Holmes supported the eugenics
movement.3 6 Left unchecked, this kind of eugenic thought pervaded
legislation during the early half of the twentieth century. For example,

the Eugenics

Records

Office championed

the

passage of The

Immigration Restriction Act of 1924, hoping to keep bloodlines "pure"
by controlling who could live in America. 37 Midcentury, the eugenic

English statistician and father of eugenics Francis Galton built on Mendel's
33.
foundation by collecting statistical information on rabbits' intelligence and physical
capabilities in the hopes of someday improving human reproduction. Galton defined
eugenics as the idea of "improving stock ... to give to the more suitable races or strains
of blood a better chance of prevailing speedily over the less suitable .... " Galton's work
inspired and combined with that of his cousin, Charles Darwin, to become so powerful it
influenced governmental policies around the turn of the twentieth century through an
ideology known as Social Darwinism. FRANcIS GALTON, INQUIRIES INTO HUMAN FACULTY
AND ITs DEVELOPMENT 17 n.1 (Gavan Tredoux ed., 2d ed. 1907); see LEVINE, supra note

32, at 3.
34.
See LEVINE, supra note 32, at 4 (describing Mendel's pea plant experiments
as the birth of gene editing and eugenics). Also note that genes can manifest differently
based on environment, but they cannot be fundamentally changed. But see Danielle
Simmons,

Epigenetic

Influences

and

Disease,

NATURE

(2008),

https://www.nature.com/scitable/topicpage/epigenetic-influences-and-disease- 895/
[https://perma.cc/U6KS-GUFD] (archived Sept. 16, 2020) (explaining that while our
fundamental genes cannot be altered, their expression can change depending on
environmental factors; for example, malnutrition before puberty causing cardiovascular

disease in children who were not especially genetically susceptible to that disease).
35.
See Seema Mohapatra, Politically Correct Eugenics, 12 FIU L. REV. 51, 5354 (2016); LEVINE, supra note 32, at 18 (describing "Fitter Family" awards given to
families who entered and won eugenics contests in interwar America); Melillo, supra
note 16, at 768-69. See also Buck v. Bell, 274 U.S. 200, 208 (1927) (Justice Holmes upheld
state-forced sterilization of "unfit" people).
36.
See Mohapatra, supra note 35, at 53.
See id.
37.
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movement reached its most horrifying, unspeakably tragic iteration in

Hitler's Nazism that led to the death of millions of Jewish people in the
Holocaust. 38
A far less extreme version of eugenic thought appeared around the
1970s, when scientists created in vitro fertilization (IVF) as a way of
alternative reproduction. 3 Scientists could examine the fertilized
embryos for chromosomal or genetic flaws before even implanting the

embryo into the mother. Prenatal technology also advanced such that
parents could detect genetic mutations before birth 40
Today, with technologies like CRISPR/Cas-9, the benefit of
improving human genes can potentially be available not only to future

generations, but to the consumers themselves.4 1 For example, a
research group created a nanocapsule that effectively and accurately
delivers a largely customizable CRISPR Cas-9 protein into target cells,
which can be stored in a frozen powder and easily administered in

different dosages. 42 While CRISPR has the potential to help many
people,

eugenic

history

illustrates

how

dangerous

gene-editing

technology can be. Considering both the potential benefits and dangers
of gene editing, the force of CRISPR/Cas-9 is limitless and must be
3
regulated. 4

B. The Discovery of CRISPR
The

nature

of

CRISPR's

discovery

helps

to

explain

its

mechanisms, and it also demonstrates the truly global character of

See Daniel J. Kevles, The Historyof Eugenics, 32 no. 3 ISSUES IN SCI. & TECH
38.
[https://perma.cc/D7WC-RVWE]
https://issues.org/the-history-of-eugenics/
(2016),
(archived Sept. 6, 2020) (describing how Hitler manipulated eugenic thinking to incite
Aryan supremacy and anti-Semitism in the Nazi party to tragically kill millions of
Jewish people); Melillo, supra note 16, at 769-70 (connecting the American eugenic
movement to the Holocaust in Germany).
See Kevles, supra note 38 (demonstrating that even the advent of IVF
39.
brought about bioethical criticism about consent and eugenics); Melillo, supra note 16,
at 771 (noting that the clinical and scientific communities worry that gene editing could
overstep ethical boundaries, exemplified in "designer babies" whose traits have been
selected before birth).
40.
See Kevles, supra note 38.
See id.
41.
See Guojun Chen, Amr Abdeen, Yuyuan Wang, Pawan Shahi, Samantha
42.
Robertson, Ruosen Xie, Masatoshi Suzuki, Bikash Pattnaik, Krishanu Saha & Shaoqin
Gong, A BiodegradableNanocapsule Delivers a Cas9 Ribonucleoprotein Complex for in
Vivo Genome Editing, 14 NATURE NANOTECHNOLOGY 974, 974-79 (2019) (explaining
mechanics and methods used for developing and testing the nanocapsule); see also

Francis Collins, Nano-Sized Solution for Efficient and Versatile CRISPR Gene Editing,
NA'L INSTS. HEALTH, https://directorsblog.nih.gov/2019/09/17/nano-sized-solution-forvisited
Jan.
17,
2020)
(last
efficient-and-versatile-crispr-gene-editing/
[https://perma.cc/MCV6-VNTL] (archived Sept. 6, 2020) (evaluating the progress and
potential applications of the Chen et al. research group).
43.
See Kevles, supra note 38.
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gene-editing technology.4 4 Scientists in Spain and France spearheaded

the

earliest advances

towards CRISPR

technology

when they

discovered the possibility of conferring viral immunity

through

archaeal research and biological weapons research around 2005.45 By
2008, Dutch researchers uncovered CRISPR's precise cutting ability,
and American scientists discovered its programmability.4 6 At the same
time, both German and Russian scientists added to the unveiling of
CRISPR's full potential in adding tracrRNA and successfully
transferring CRISPR in other bacteria. 4 7
The discovery process of CRISPR culminated in three papers
published in 2012. Almost simultaneously, Jennifer Doudna and
Emanuelle Charpentier, who recently won the Nobel Peace Prize for

their CRISPR research, published their findings that RNA could
function in vitro, Feng Zhang reported his successful genome editing
in mammalian cells, and George Church reported his successful

genome editing of human cells. 48 Since the publication of those papers,
CRISPR's potential has been recognized by the global public, as

49
evidenced by the dramatic uptick of CRISPR in Google searches.
CRISPR's mechanics set it apart from other gene-editing technologies

because it is easier to use, less expensive, and more accurate. 5 0 Today,
scientists use CRISPR to test for genetic mutations in mammals, some
including humans, but only in somatic cells.

44.
See Eric S. Lander, The Heroes of CRISPR, 164 CELL 18, 18-20 (2016)
(outlining CRISPR's global discovery process).
Beginning in 1989, Fransisco Mojica studied archaeal microbes (single-celled
45.
organisms) in Mediterranean marshes off the Spanish coast when he first discovered
palindromic, regularly spaced bases never seen before in microbes. He published several
papers on the topic. Coinciding with Mojica's story, Gilles Vergnaud of France's Ministry
of Defense also discovered the CRISPR pattern in their microbiological research. See id.
at 18-22.
46.
See id. (recounting Phillipe Horvath's Cas-9 research, John van der Oost's
work for the Dutch National Science Foundation, and Luciano Marrafini and Erik
Sontheimer's targeting research at the University of Chicago).
47.
Emanuelle Charpentier and Jdrg Vogel further found that tracrRNA was
necessary for processing crRNA, and thus necessary for overall CRISPR function.
TracrRNA helps process CRISPR and cleave it to DNA. Meanwhile in Russia, Virginijus
Siksnys discovered that CRISPR could be transferred into other bacteria and maintain
the same effects as it did in the original organism, making it easier and cheaper to use.
See id. at 23-24.
48.
See id. at 24-25.
49.
See id. at 26.
50.
See Sarah Polcz & Anna Lewis, CRISPR-Cas9 and the Non-Germline NonControversy, 3 J. L. & BIOSCIENCES 413, 414-15 (2016).
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C. The Ethics of CRISPR
The use of CRISPR on humans sparks fundamental ethical
concerns in the global community. 51 Typically, scholars divide these
concerns between somatic and germline cell editing because each
implicates distinct issues-germline modification will be inherited as
a permanent part of the human gene pool, while somatic cell editing
affects only an individual.5 2 Within somatic cell editing, a further
divide lies between whether one views somatic cell editing on a
continuum of gene-editing technologies, or as a new, unprecedented
technology.5 3 The "continuum" school of thought, which includes

organizations such as the International Summit on Human Gene
Editing and the National Academies of Sciences, Engineering, and
Medicine, believes that as long as certain safety and efficacy standards
are met, somatic gene editing should be no different than other medical
interventions.5 4 The "unprecedented" school of thought agrees that
somatic editing begs similar questions to other medical interventions,

but concludes that it should ultimately be treated differently because
of additional, significant questions surrounding the adequacy of
of gene-editing
commercialization
the
regulations,
existing
55
technologies, and the equity of access in such a dynamic field.
The following examples illustrate those adequacy of governance,
commercialization, and equity issues exclusive to the somatic
application of CRISPR. 56 Concerning the adequacy of existing

regulations, recent experiments suggest that certain genes can
predispose individuals to violence based on their personal experiences,
and CRISPR can be used to modify that gene to reduce the violent
nature of the individual. 57 Given the low cost and availability of

CRISPR treatment, if an individual refused to modify his or her
"violent" genes and later committed a violent act, questions arise over
58
how a person ought to be punished for refusing the treatment.
Similarly, but further down the road, governments could cut eligibility
for disability funding and treatment for individuals who could be cured

51.
See, e.g., Baltimore, Baylis, Berg, Daley, Doudna, Lander, Lovell-Badge,
Ossorio, Pei, Thrasher, Winnacker & Zhou, supra note 5 (calling together the global
scientific community in order to address changes in gene-editing technology because they
are significant enough to merit a change in ethical standards).
See WHO, supranote 22, at 2; Polcz & Lewis, supra note 50, at 417-18; NAT'L
52.
ACADs. OF SCIs., ENG'G, AND MED., supra note 8, at 83.
See WHO, supra note 22, at 2-3.
53.
54.
See id.
See id. at 3-4.
55.
See Polcz & Lewis, supra note 50, at 417-22.
56.
See id. at 418-19. These examples are somewhat theoretical given the
57.
current state of CRISPR (i.e., CRISPR has not been successful inserted into a human
brain yet), but could certainly happen in the future.
58.
See id.
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by CRISPR but refuse. 59 Finally, application of CRISPR to somatic
cells could enhance athletic performance, and because detection of gene
therapy is difficult, a new kind of "gene-doping" advantage in sports
could be hard to prevent. 60 Some of these modifications are timesensitive, so the application of CRISPR on minors sparks controversy
surrounding consent: Should guardians or children themselves provide
consent for time-sensitive traits like height, or secondary sexual

characteristics 6 1 for those who identify as transgender?6 2 Other legal
implications include allowing insurance companies to incentivize

genetic modification for women with a predisposition to breast cancer
through discovery of the BRCA1 gene, or those with a predisposition to
a harmful addiction like nicotine.6 3 Curbing criminal violence,
changing legal entitlements to disability accommodations, and having

the ability to choose one's own characteristics each implicate policy
decisions far beyond the consenting individual, which blurs the
rationale for dividing conversations based on germline and somatic

editing. 64
The commercialization of gene-editing technologies manifests
clearly in the debate about enhancement and therapeutic use. The
scientific community has tried to limit somatic editing to only

therapeutic uses, though the distinction between therapeutic use and
enhancement has become increasingly unclear. 65 The National
Academies of Sciences, Engineering, and Medicine have defined
therapy to encompass both the treatment and the prevention of

See id. at 420-21.
59.
See id. at 422-23.
60.
61.
Secondary sexual characteristics are those characteristics that develop after
puberty, such as men's facial hair. See, e.g., Elizabeth J. Susman, Renate M. Houts,
Laurence Steinberg, Jay Belsky, Elizabeth Cauffman, Ganie DeHart, Sarah L.
Friedman, Glenn I. Roisman & Bonnie L. Halpern-Felsher, Longitudinal Development
of Secondary Sexual Characteristicsin Girls and Boys Between Ages 9%2 and 15% Years,
ARCH PEDIATRIC ADOLESCENCE MED. 1, 2 (2010).
62.
See id. Currently, this type of modification would be very difficult to
accomplish because it is multigenic.
63.
See Polcz & Lewis, supra note 50, at 424; see also Mukherjee, supra note 17
(discussing the novelty of the label "pre-vivors" for individuals who survived a genetic
disease he or she never actually had).
64.
See Polcz & Lewis, supra note 50, at 423 (discussing the implications of
changing "immutable" traits, and suggesting problems using this science on minors).
65.
See id. (explaining the ability to change traits for individuals in order to
better "suit their life choices"); NAT'L ACADS. OF SCIS. ENG'G AND MED., supra note 8, at

110 (recommending that public policy debates discuss the use of somatic cell genome
editing outside of the treatment of disease or disability); Ruha Benjamin, Interrogating
Equity:A Disability JusticeApproach to Genetic Engineering,in COMMISSIONED PAPERS
FOR THE INTERNATIONAL

SUMMIT ON

HUMAN GENE EDITING

48,

48-51

(2015),

https://sites.nationalacademies.org/cs/groups/pgasite/documents/webpage/pga_170455.p
df (last visited August 31, 2020) [https://perma.cc/UZ5V-J8JA] (archived August 31,
2020) (discussing the fallacies associated with the "ableist" norms that somatic cell gene
editing is developed to cure and exploring the balance between these cures and the
desires of individuals to enhance the human body).
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diseases, and enhancement as genetic "interventions that are intended
to improve a bodily condition or function beyond what is needed to
restore or sustain health." 66 The international scientific community

generally condones therapeutic genetic modification as safe and
beneficial, but some situations make distinguishing enhancement from

therapy difficult. 67 To illustrate, most people consider it therapy when
doctors reduce the cholesterol level of a patient with coronary heart
disease or preventative therapy to genetically reduce that patient's

sibling's cholesterol, but might consider it enhancement when doctors
lower the cholesterol level of a healthy, young individual below what is
"normal." 68 Definitionally, "normal" in a genetic conversation refers to
what is typical for the human range of capabilities in phenotypical or

physical manifestation of a trait, and "natural" refers to the genes that
create the range of "normal" characteristics, whether advantageous or
disadvantageous. 69 At the heart of these distinctions lies the question
of how to define a disease. 70 Defining a disease can reveal societal
preconceptions, for example, as many individuals may hold different
opinions about whether a certain genetic traits and their resulting
conditions need cures. For example, individuals who are deaf or blind

often state they would not want to be cured of their deafness or
blindness because it is a part of their identity, and they would not be
the same person but for their condition. 7 1 Because defining a disease
can differ greatly, individual nations should decide for themselves who

will decide what is "normal" and what constitutes a "disease" in order
72
to regulate somatic cell editing.
73
Finally, somatic cell editing also implicates fairness concerns.

Some schools of thought focus on the fairness of the interventional
effect of gene editing, rather than the distinctions previously
mentioned. 74 Classifying what genetic characteristics are "fair" largely

depends on what is considered "normal," and because the range of
"normal" human characteristics for any one gene is so large, fairness
is a very fluid category (think about the difference in humans' sprinting

66.

NAT'L ACADS. OF SCIS., ENG'G, AND MED., supra note 8, at 145.

67.
68.
69.
70.

See
See
See
See

71.

See NAT'L ACADS.

id.
id. at 147.
id. at 139.
id. at 147-48; Mukherjee, supranote 17.
OF

ScIS.,

ENG'G, AND MED., supra note 8,

at 148;

Mukherjee, supra note 17.
72.

However,

even individual countries

defining terms

like "disease"

and

"normal" is an imperfect solution because it usurps the individual's autonomy in making
these decisions for oneself based on one's culture and experiences. See infra Part IV for

further discussion.
See, e.g., NAVL AcADS. OF Scis., ENG'G, AND MED., supra note 8, at 147-50
73.
(discussing the concept of fairness in the context of somatic cell gene editing).
74.
See id. at 149.
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speeds, for example). 75 Societies usually increase access for citizens
through raising medical funding and insurance coverage to ensure
equity for other medical interventions like hip replacements or laser

eye surgery, but with CRISPR, societies have certainly restricted
funding and insurance coverage. 76
But supporters of a Rawlsian, equity-based theory of justice would
argue the contrary. 77 Under this theory of equality-based reciprocity,
fairness is less about individual access and more about societal
distribution, so a genetic enhancement to an individual would only be

tolerated if distributed equitably in such a way that advanced the
common good. 78 In reality, genetic enhancement through gene editing
would likely not be the principal source of inequality in a society, if it

had any effect at all. 79
Many countries prohibit germline cell modification because of its
serious ethical implications. 80 There are three major ethical issues
with germline modification: permanently affecting the health of future
generations, producing unpredictable and possibly irreversible results,

and the lack of consent because the people who would be affected by
the modification have not yet been born. 8 1 The debate about germline
cell editing can be examined through a study of the benefits and
detriments of its use for basic research (using CRISPR to test for
editing precision and efficiency) or clinical research (applying tested
science to living humans). 82 Basic research, however, can require the
use of human embryos, which sparks ethical controversy among
83
scientists over the source of the embryo and the length of testing.
Clinical research is a hotly debated area of CRISPR application, with
scholars disagreeing primarily about whether there is a need for

CRISPR modification when other technologies can accomplish many of

While training and practice can contribute to a faster speed, humans are
75.
born with baseline capacity for sprinting because of genetic factors like a fast twitch
muscle. In this context, what is the "fair" level of fast twitch muscle modification-Usain
Bolt or a high school track runner? See id.
76.
See id.
77.
See id. at 149-50.
78.
See id.
79.
See id.
80.
For example, the United States had an effective moratorium on germline
modification. See id. at 183-90.
81.
See Polcz & Lewis, supra note 50, at 415 (quoting American Medical
Opinion 2.11 Gene Therapy, https://web.archive.org/web/201604
Association,

06074109/https://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/codemedical-ethics/opinion211.page (last visited Nov. 10, 2020) [https://perma.cc/AZV8SXSX?type=image] (archived Nov. 10, 2020)); NAT'L AcADS. OF SCIS., ENG'G, AND MED.,
supranote 8, at 137-38.
82.
See WHO, supra note 22, at 2-3; Rosario M. Isasi & Bartha M. Knoppers,
Mind the Gap: Policy Approaches to Embryonic Stem Cell and Cloning Research in 50
Countries, 13 EUR. J. HEALTH L. 9, 12-16 (2006).
83.
See WHO, supra note 22, at 4-6.
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84
the same results, and about how best to regulate the technology. The
regulatory debate centers on the safety and morality of the
intergenerational effects of gene editing on the germline. One's position

usually reflects one's belief as to whether CRISPR is an unprecedented

85
technology or like other assisted-conception technologies. Still other
concerns outside of safety and regulation arise, such as the lack of

consent from future generations, the threat to the dignity of
humankind, the changing of cultural norms, and the exacerbation of
86
socioeconomic inequality.

III. DIFFERENT APPROACHES TO REGULATING CRISPR

Given the complex ethical considerations surrounding CRISPR

and its rapid rise to practical use over the last two decades, regulating
it and the future of gene editing proves both extremely important and
difficult. 87 The existing international framework is mostly made up of

broad standards or goals, like the Universal Declaration on the Human
Genome
Summit

and Human Rights (Declaration) and the International
on Human Gene Editing.88 These agreements permit

countries to select their own regulations for gene editing. Countries'
regulations reflect the view of their citizens, while also supporting the
broad goals of the agreements. 89 The Oviedo Convention, a more

See id. at 6-7 (considering the argument for a need of germline editing for
84.
couples who desire to have a genetically related child without passing on a genetic
illness);

NUFFIELD

COUNcIL

ON

BIOETHICS,

GENOME

EDITING

AND

HUMAN

REPRODUCTION 96 (2018), http://nuffieldbioethics.org/wp-content/uploads/Genome(last visited Sept. 5, 2020)
editing-and-human-reproduction-FINAL-website.pdf
[https://perma.cc/ED2C-NA4P] (archived Sept. 5, 2020) (arguing that since genome
editing is only justified when it is beneficial to the future child's health, and existing
technologies accomplish that already, genome editing could be prohibited); Brooke E.
Hrouda, "PlayingGod?'" An Examination of the Legality of CRISPR Germline Editing
Technology Under the Current International Regulatory Scheme and the Universal
Declarationon the Human Genome and Human Rights, 45 GA. J. INT'L & COMPAR. L.
221, 241 (2016).
See WHO, supra note 22, at 8; Hrouda, supra note 84, at 232-33.
85.
See WHO, supra note 22, at 9. Compare Inigo de Miguel Beriain, Should
86.
Human Germ Line Editing be Allowed? Some Suggestions on the Basis of the Existing
Regulatory Framework, 33 BIOETHICS 105, 107-08 (2018) (arguing that the human
germline is always changing, so changes made through gene editing should not require
special consideration), with G.A. Res. 53/152, Declaration on the Human Genome and
Human Rights (Dec. 9, 1998) (intimating that the human genome has an inherent
dignity that must be protected from human intervention).
Hrouda, supra note 84, at 229-32.
87.
General Conference of UNESCO, Universal Declaration on the Human
88.
Genome and Human Rights, arts. 1-2, U.N. Doc. A/53/152 (Dec. 9, 1998) [hereinafter
Declaration];Convention for the Protection of Human Rights and Dignity of the Human
Being with Regard to the Application of Biology and Medicine: Convention on Human
Rights and Biomedicine art. 1, Apr. 4, 1997, E.T.S. 164 [hereinafter Oviedo Convention].
Hrouda, supra note 84, at 229-32.
89.
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specific agreement, provides more concrete steps for countries that

'

ratify it, but many decisions are still left up to individual nations.9 0
The United States, the United Kingdom, and Japan each serve as
meaningful examples of gene-editing research governance within an
individual country. Each of these countries regulate gene-editing
technologies in different ways, yet each are on the cutting edge of
innovation in this field. 9
A. Existing TransnationalRegulations
Though science transcends national borders, much of the existing
transnational law does not bind countries.9 2 Undoubtedly, the
Universal Declaration on the Human Genome and Human Rights

exhibits an excellent philosophy concerning gene-editing technology,
but merely influences specific regulation because it is not binding
law.93 The International Summit on Human Gene Editing compiled

updated, thorough data from experts around the world concerning
ethical dilemmas in editing the genome via somatic and germline cells,
but again, it fails to bind any countries. 94 And finally, the Oviedo
Convention binds ratifying nations to its broad terms, but leaves open
many specific regulatory questions. 9 5 Though each of these agreements

fall short of regulating gene editing internationally, they are extremely
influential works on the ethics of responsible science.
1. Universal Declaration on the Human Genome and Human Rights
The United Nations Educational, Scientific, and Cultural
Organization (UNESCO)'s Declaration is not binding on any nation. 96

90.
Robert Andorno, The Oviedo Convention: European Legal Framework at the
Intersection of Human Rights and Health Law, 2 J. INT'L BIOTEcH. L. 133, 134-36 (2005).
91.
Charo, supra note 19, ¶¶ 26-41.
92.

See, e.g., Hurst Hannum, The Status of the Universal Declarationof Human

Rights in National and InternationalLaw, 25 GA. J. INT'L & COMPAR. L. 287, 317-18
(1996) (explaining that UN Declarations are simply a declaration of rights, but no more
than that).
93.
Hrouda, supranote 84, at 223.
94.
International Summit on Human Gene Editing, NAT'L AcADs. OF SCIS.,
ENG'G,
AND
MED.
(Dec.
3,
2015),
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID= 12032015a
(last visited Sept. 5, 2020) [https://perma.cc/GS6S-SZH4] (archived Sept. 5, 2020).
95.
Oviedo Convention, supra note 88, chs. II-XIV (presenting protocols for
regulating everything from consent to public engagement for ratification).
96.
See, e.g., Hannum, supra note 92, at 317-18 (explaining that UN
Declarations are simply a declaration of rights, but no more than that); Hrouda, supra
note 84, at 223. The United Nations defines a declaration as an instrument that
"clarif[ies] the state's position and do[es] not purport to exclude or modify the legal effect
of
a
treaty."
See
United
Nations
Treaty
Collection,
Glossary,
https://treaties.un.org/Pages/Overview.aspx?path=overview/glossary/pagelen.xml (last
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The principles laid out in the Declaration are broad, normative goals
designed to protect the human genome. 97 The United Nation's TwentyNinth General Assembly unanimously adopted the Declaration in
98
Despite its lack of
1997, and it has been widely supported since.
binding authority, the Declaration has taken an influential place in

international biomedical law as a customary common law. 99 The
United States, the United Kingdom, and Japan have indicated
approval and inclusion of the Declaration in their national governance
as member countries of the United Nations.1 00
The Declaration has three main principles: that the human
genome is part of the heritage of humanity, that individual human life

should be respected regardless of genetic makeup, and that genetic
01
This first principle is found in
discrimination cannot be tolerated.1

the first two articles of the Declaration, which proclaim that that the
human genome underpins all of humanity and therefore should be

respected as an integral part of human dignity.' 0 2 Article 10 of the
Declaration adds to the first principle by adding the second two

principles: "No research or research applications concerning the
human genome . . . should prevail over respect for the human rights,
fundamental freedoms and human dignity of individuals or ... groups
of people."' 0 3 Additionally, Article 12 ensures equal access to the
04
benefits of genetic research on the human genome to all individuals.1
The Declaration continues on to emphasize the necessity of informed
consent in genetic research, yet allows research to progress without it

if the individual does not have the capacity to consent and there is a
direct health benefit, minimal risk and burden, or, in the case of a
05
Finally, in
human embryo, a third party consents to the research.1
Article 16, the Declaration encourages individual countries to enact

visited Sept. 5, 2020) [https://perma.cc/5FJF-T2W5] (archived Sept. 5, 2020) (explaining
that declarations are not always binding).
97.
The Universal Declaration on the Human Genome and Human Rights,
https://en.unesco.org/themes/ethics-science-and-technology/humanUNESCO (2019),
genome-and-human-rights (last visited Sept. 5, 2020) [https://perma.cc/U9GZ-X5Q3]
(archived Sept. 5, 2020).
See id.; Hrouda, supra note 84, at 223 n.8.
98.
Hrouda, supra note 84, at 223.
99.
100.

Member Nations, UNITED NATIONS (2020), https://www.un.org/en/member-

states/ (last visited Feb. 26, 2020) [https://perma.cc/RH7M-PMV6] (archived Sept. 5,
2020).
UNESCO Adopts Universal Declarationon the Human Genome and Human
101.
Rights, EUREKALERT! (Nov. 11, 1997), http://www.eurekalert.org/pub-releases/199711/U-UAUD-111197.php (last visited Sept. 5, 2020) [https://perma.cc/Q69F-MTYJ]
(archived Sept. 5, 2020) (breaking down the Declaration into smaller parts); Hrouda,
supra note 84, at 232-33 (discussing three basic principles in the Declaration).
102. Declaration,supra note 88, arts. 1-2; see Hrouda, supranote 84, at 233-34.
103. Declaration,supra note 88, art. 10; see Hrouda, supra note 84, at 234.
104. Declaration,supra note 88, art. 12.
105. Id. art. 5(a)-(e); see Hrouda, supra note 84, at 235.
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their own ethics committees to constantly assess the ethical concerns
of that country's research.1 06
The Declaration's wide acceptance illustrates the global approval
of protecting the dignity of the human.1 07 Within the Declaration,
protecting the dignity of the human stands for the proposition that
there is fundamental value in one human being recognizing another
for his or her value as a human.1 0 8 Implicit in that conception of human
dignity lies the acceptance of human diversity, which symbolically
includes everything down to the human genome.' 0 9 The Declaration

subdues common fears about gene editing by emphasizing equality of
access,1 10 necessity of patients' informed consent,"' and continued,
2
individual assessment of governance by each country.1"
The Declaration falls short in some ways. The International
Bioethics Committee, the governing body charged with enforcing the
Declaration, has yet to decide whether or not "germline interventions"
contradict human dignity under the treaty.1"3 If the Committee did so,
then germline editing would be illegal under the treaty. Additionally,

the Declaration rests upon the assumption that the human genome is
inherently protected under universal human rights, but some
scientists have argued that there is no such thing as a distinctly human
genome-that even nonhumans have genomes similar to humans, so
no special protection of the human genome needs to be afforded in the
name of universal human rights.114

106.

Declaration,supra note 88, art. 16.

107. See Hrouda, supra note 84, at 234.
108. See Mette Labach, What is Human Dignity?, NAT'L U. IR. 1, 1-2 (2004),
http://eprints.maynoothuniversity.ie/392/1/HumanDignity.pdf (last visited Sept. 5,
2020) [https://perma.cc/2G75-HC2T] (archived Sept. 5, 2020) (positing a historical
account of what human dignity means).
109. See id. (emphasizing the value of each individual recognizing others).
110. See, e.g., NAT'L AcADS. OF SCIS., ENG'G, AND MED., supra note 8, at 147-50
(discussing the concept of fairness in the context of somatic cell gene editing).
111. See, e.g., id. at 30-34 (stating the principles underlying the United States'
requirement of voluntary, informed consent from the patient).

112. See, e.g., id. at 45-48 (explaining the role of IRBs in the United States' system
of governance provides an example of continued, individualized assessment of research
governance).
113. NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 115.
114. Id. (arguing that UNESCO's symbolic importance of the human genome
might be biological fiction since there is no set of genomic variations humans have that
nonhumans do not have, and if there were distinct human variations, it would preclude
any further evolution).
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2. International Summit on Human Gene Editing
The International Summit on Human Gene Editing (Summit)
aims to unify participating countries on bioethical policies through

occasional meetings where experts present different findings to inform
115
Each of these two Summits included
the Summit's statement.
116
The first Summit's statement
experts from all over the world.
encouraged cautious and scrutinizing regulation of somatic cell editing
moving forward, but specifically forbade germline editing as too

dangerous in light of the lack of research and understanding in 2015.117
The second Summit was held in Hong Kong, which is where Dr. He
announced his completed modification of human embryos in November

2017, discussed in Part

J.118

Each Summit produced commissioned

papers, presentations, and guidelines for the international community,
119
The official
though none of these were binding on any nation.

statement from the 2018 Summit meeting affirmed careful governance
but approved somatic cell research and again strongly discouraged
germline research until a later time. 120
The International Summit represents a new vision for selfgovernance of scientific research-allowing professional bodies,
learned societies, and national academies to create rules based off their
expertise and data and enforce them as a community. 12 1 The 1975
Asilomar conference, which served almost as a template for the
International

Summit,

highlighted

the value

of self-regulation.

Scientists met at the conference to discuss protocols for the
development of recombinant DNA technology and produced widely
accepted biosafety practices.12 2 Spurred by advances in CRISPR
research, the scientific community pushed for self-regulation in gene12 3
editing technology, which culminated in the International Summit.

115. InternationalSummit on Human Gene Editing, supra note 94.
116. Id.
117. Id.
118. Baltimore, Charo, Daley, Doudna, Kato, Kim, Lovell-Badge, Merchant, Nath,
Pei, Porteus, Skehel, Tam & Zhai, supra note 9.
119. Id.; Baltimore, Baylis, Berg, Daley, Doudna, Lander, Lovell-Badge, Ossorio,
Pei, Thrasher, Winnacker & Zhou, supra note 5.
120. Baltimore, Baylis, Berg, Daley, Doudna, Lander, Lovell-Badge, Ossorio, Pei,
Thrasher, Winnacker & Zhou, supra note 5; Baltimore, Charo, Daley, Doudna, Kato,
Kim, Lovell-Badge, Merchant, Nath, Pei, Porteus, Skehel, Tam & Zhai, supra note 9.
121. See Baltimore, Charo, Daley, Doudna, Kato, Kim, Lovell-Badge, Merchant,
Nath, Pei, Porteus, Skehel, Tam & Zhai, supra note 9 (releasing only a statement from
the summit for countries to incorporate into their existing protocol and regulation).
NUFFIELD COUNCIL ON BIOETHIcS, supra note 84, at 129. But see
122.
Charo, supra note 19 (suggesting that self-regulation among scientists led to overly strict
guidelines and shortage of supplies gametes and embryos needed for research in the US).
123. NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 129 (describing the
earliest CRISPR scientists' move for regulation of CRISPR, specifically barring germline
modification and creating internationally agreed upon objectives for CRISPR research).
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3. Oviedo Convention

The Council of Europe emphasized the dignity of the human
genome in its 1997 European Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to the Application
of Biology and Medicine: Convention on Human Rights and
Biomedicine, now known as the Oviedo Convention. 124 The
Convention's treaty was adopted by nineteen European countries, with
the United Kingdom, France, and Germany notably missing. 125
Unlike UNESCO agreements and the International Summit, the
Oviedo Convention requires each ratifying nation to adopt the
recommendations as laws in their own countries upon ratification,
without using any of the common European institutions to enforce the
law.126 The Convention is also an attempt to regulate the entirety of

human bioethics, not just genetic research

or other individual

components of human rights or biomedicine. 12 7

However, like the UNESCO agreements, the Convention provides
a general framework on which each country should base its own
specific protocols. 128 The Convention can only be protected in courts of
an individual nation, not the European Court of Human Rights, which

many scholars point out as a flaw in the treaty. 129 Where the
Convention provides for relative human rights, the common law of the
European Court of Human Rights may apply because the language
used is practically identical.130

More than anything, the Oviedo Convention emphasizes the
dignity of the inheritance of the human genome over scientific progress

124. See Andorno, supra note 90, at 133 (explaining that the Council of Europe is
made up of 46 European nations with the mission of promoting both human rights and
democratic values in Europe). The Council of Europe held the European Convention for
the Protection of Human Rights and Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on Human Rights and Biomedicine,
now known as the Oviedo Convention, in 1997.
125. See id. at 134 (explaining that the United Kingdom did not adopt the
Convention because it was too restrictive, Germany

refused because it was too

permissive, and France refused because of its own simultaneous bioethics law reform).
126. See id. at 134-36; Oviedo Convention, supra note 88, art. 1. This means that
the adopting countries of the Oviedo Convention must agree with every word of the
Convention and defend it in their own courts.
127. See Oviedo Convention, supra note 88, pmbl. (using generalized terms like
"biology" and "medicine" affecting "human dignity"); Andorno, supra note 90, at 134.
128. See Oviedo Convention, supra note 88, chs. II-XIV (presenting protocols for
regulating everything from consent to public engagement for ratification); Andorno,
supra note 90, at 134.
129. See Oviedo Convention, supranote 88, art. 1, para. 2 ("Each Party shall take
in its internal law the necessary measures to give effect to the provisions of this
Convention."); Andorno, supra note 90, at 135-36 (specifically noting that without
judicial enforcement in each member country, the rights laid out in the Convention will
have no real power).
130. See Andorno, supra note 90, at 136.
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or societal preference. 13 1 In that spirit, it seeks to protect equality of
access to healthcare for all humans, the right to informed consent, and
the right to privacy of information.1 32 While it protects against genetic
discrimination

and forbids

modifications

of the

human genome

3
completely, it fails to take a position on human cloning.1 3 The

Convention sets up a general framework for biomedical research, but
defers the task of defining "embryo research" to the individual
nations.1 3 4 Without defining embryo research, the Convention fails to

resolve the controversy surrounding the use of embryos in research,
which is a fundamental part of gene-editing research.1 35
The Oviedo Convention directly prohibits interventions on the
human genome in Article 13.136 However, when the Convention was
drafted in 1997, the technology was not close to making germline
modifications a reality.1 37 With CRISPR's invention, many member
states are pressing to revisit Article 13 via Article 32, which allows the

Convention to be revised starting five years after its ratification.1 38
B. Sample Countries
At the national level, countries have adapted their existing

systems to the growth of gene-editing technology with varying degrees
of success. The United States uses its regulatory system to delegate
regulatory authority over scientific development to specialized
government agencies, which are designed to be responsive to the
American

public.139

The

United

Kingdom

maintains

extensive

statutory control of all reproductive technology, both pre- and postmarket.14 0 Finally, the Japanese government delegates much of the
initiative of scientific regulation to academic societies and the

131.
132.
at 138-39.
133.
at 140-41.
134.
135.
136.

See id. at 137; Oviedo Convention, supranote 88, pmbl., art. II.
See Oviedo Convention, supra note 88, arts. 3, 5-10; Andorno, supranote 90,
See Oviedo Convention supra note 88, arts. 11, 13; Andorno, supra note 90,
Interestingly, the Convention specifically bans sex selection in vitro.
See Andorno, supra note 90, at 141-42.
See id. at 142.
See Oviedo Convention, supra note 88, art. 13.

137.

See NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 117.

138.

See id.

139.

See NAT'L ACADS. OF SCIS., ENG'G, AND MED., supra note 8, at 103-05, 171-

72 (outlining the process of FDA approval of somatic cell gene editing clinical testing,
standard laboratory practices including consent, and IRB continued review of ethics and
safety).
140. See Robin Lovell-Badge, The Regulation of Human Embryo and Stem-Cell
Research in the United Kingdom, NATURE REVS. 998, 1000 (2008) (statutorily requiring
HFEA approval, donor consent, and independent ethics committee approval of geneediting technologies).
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Though these approaches differ, their regulatory systems

serve as a model for other countries because they are on the cutting
edge of gene editing.
1. The United States: Innovation Leads to Hesitancy

Currently in the United States, somatic cell clinical applications
and research for treatment or prevention of disease and disability are
moving forward, while clinical applications and research on germline
editing are firmly prohibited.142 The Food and Drug Administration

(FDA) regulates somatic cell applications and research.14 3 Somatic cell
research is treated like other laboratory research-this includes
internal biosafety review, general laboratory practice standards, and
special policies applicable to the use of human cells, tissue, or embryos
in research.14 4
In the United States, research proposals involving CRISPR must
be approved through a multistep process. First, the FDA must approve

a confidential Investigational New Drug (IND) application, and then
the FDA and an institutional review board (IRB) continually review

the progress and techniques over the period of research.14 5 In addition
to the reviews done by the IRB and the FDA, meetings held at the
National Institutes of Health (NIH)'s Novel and Exceptional

Technology and Research Advisory Committee (NExTRAC) facilitate
public engagement.1 4 6 The NIH's review aims to determine the amount
of funding, if any, that it will give to the research proposal.1 47

141. See Anu Shukla-Jones, Steffi Friedrichs & David E. Winickoff, Gene Editing
in an InternationalContext: Scientific, Economic and Social Issues Across Sectors 22, 2728 (OECD Sci., Tech., & Indus., Working Paper No. 04, 2018) (noting a Japanese Cabinet
Office member offered Japan's panel and public engagement sessions as an example of
inclusive regulation).

142. See NAT'L AcADs. OF ScIs., ENG'G, AND MED., supra note 8, at 183-90
(discussing the existing U.S. regulations of somatic cell application and research and
germline cell application and research and recommending regulations for the
advancement of gene-editing technology both in the U.S. and generally); Baltimore,
Charo, Daley, Doudna, Kato, Kim, Lovell-Badge, Merchant, Nath, Pei, Porteus, Skehel,
Tam & Zhai, supranote 9 (prohibiting gene editing of human germline cells).
143.
See NAT'L AcADs. OF ScIs., ENG'G, AND MED., supra note 8, at 184-86
(focusing on somatic cell application and research governance).
144. See id. at 184 (policies factor in any identifying information that could be
found in the material, requiring a form of consent from the subject and additional
institutional board review [IRB] if any is found).
145. See id. at 103, 171 (outlining the process of approval of somatic cell gene
editing clinical testing).
146. See id. at 103.
147. See Hrouda, supra note 84, at 230-31. Other sources of funding besides the
NIH are available.
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The NIH approves those somatic applications with easily
trackable and identifiable risks. 148 Nonbinding guidance from the FDA
implies that the less chance of long-term risk, the less monitoring
149
If allowed on the
throughout the clinical research will be required.
market, a gene-altering drug would have special warning labels,
require patient consent, be subject to post-market data analysis, and
be subject to complete withdrawal from the market should any
indication of danger or ineffectiveness be shown.1 50 Interestingly,

though, the United States does not regulate how physicians use the
product once it has been released to the market. 151
American citizens have shown support for the clinical use of

somatic cell gene editing for the prevention of disease and disability
using the democratic processes already in place in the governmentby participating in congressional elections and public commenting
1 52
Additionally, the NIH and
under the Administrative Procedure Act.

the NExTRAC make their reviews open to the public (in person or via
broadcast) and send findings to an email list of those who signed up for
updates. 153 Finally, there are seven national ethics committees that
work to encourage public participation in decision-making and advise

54
the federal government on its policymaking on these topics.1
However, the death of Jesse Gelsinger in 1999 indelibly marked
the discussion about somatic cell gene editing research in the United
States. 155 Gelsinger was a patient of Dr. Wilson at the University of

Pennsylvania. Specifically, Gelsinger was a participant in his trial
aiming to modify somatic cells in children born with orinithine

transcarbamylase (OTC).1 56 Gelsinger died due to an adverse reaction
to the vector through which the doctors had delivered the gene-editing

148. See NAT'L AcADS. OF ScIs., ENG'G, AND MED., supra note 8, at 104 (noting
these reviews take into account "stakeholder and societal perspectives about the value
of benefits and the tolerability of risks, . . . the existence and effectiveness of alternative
treatments, disease severity, risk tolerance of affected patients, and potential for
additional insight from postmarket data").
149. See id. (suggesting 15 years of posttrial observation).
150. See id. at 104-05 (also noting that the potential off-label use of these drugs
might merit further restriction).
151. See Charo, supra note 19. The FDA does not regulate clinical practice, but
doctors and drug/device representatives are partially regulated through the Health and
Human Services agency through laws like HIPPA. See Introduction:About HHS, DEP'T
OF

HEALTH

AND

HUM.

SERVS.,

https://www.hhs.gov/about/strategic-

plan/introduction/index.html (last visited Sept. 5, 2020) [https://perma.cc/25FS-V3A7]
(last archived Sept. 5, 2020).
152. See NAT'L AcADS. OF SCIs., ENG'G, AND MED., supra note 8, at 169.
153. See id. at 170-71.
154. See id. at 172.
155. See Lynn Smith & Jacqueline Fowler Byers, Gene Therapy in the PostGelsinger Era, 4 JONA's HEALTHCARE L., ETHICS & REG. 104, 107 (2002).
156. See id. at 106 (explaining OTC as a disease where an X chromosome is either
missing or defective, preventing the liver from producing enough OTC to remove
ammonia from the blood).
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material. 157 The FDA and NIH barred Dr. Wilson from participating
in clinical trials without restrictions until February 2010 and required

him to write a letter
returning to clinical
attributed blame to
patient consent form,

detailing his experiences from the trial before
trials.1 58 The NIH's and FDA's investigations
the research team specifically concerning the
which led both patients and the FDA to believe

no deaths occurred in the previous testing on animals.1 59 The later

investigation also highlighted the neglect of the university's IRB for
allowing the trial to continue on Gelsinger, whose ammonia levels were
abnormal at the time of the fatal injection. 6 0 Finally, as later came to
light, the lead doctor had a financial interest in the trial's success,
which led to a lawsuit from the Gelsingers.'61
In response to the inundation of review requests the NIH received
after Gelsinger's death, the FDA and NIH harmonized their
requirements, which streamlined the supervision burden on
researchers to balance the confidentiality for businesses looking to
profit from the technology in trial (because much of the review process
is open to the public) and appropriate disclosures throughout trials for
safety and accountability. 16 2 However, the damage that Gelsinger's
death caused to the public trust in the field of gene-editing research
1 63
and the responsibility cast on IRBs was undeniably severe.

Gene-editing research in the United States slowed partly because
of Gelsinger's death and because of the functional bar on research
using human embryos without the goal of pregnancy. The DickeyWicker Amendment prohibits federal funding for research using

human embryos without the goal of pregnancy, but some states and

157. See id. at 107.
158. See Robert Steinbrook, The Gelsinger Case, in OXFORD TEXTBOOK OF
CLINICAL RESEARCH ETHICS 110, 116 (Ezekiel J. Emanuel, Christine C. Grady, Robert
A. Crouch, Reidar K. Lie, Franklin G. Miller & David D. Wendler eds., 2008); Robert
Fretwell Wilson, The Death of Jesse Gelsinger: New Evidence of the Influence of Money
and Prestige in Human Research, 36 AM. J.L. & MED. 295, 301 (2010) (focusing on Dr.
Wilson's punishment, including his letter).
159. See Steinbrook, supra note 158, at 116; see also Wilson, supra note 158, at
303-16 (taking an in-depth look at Dr. Wilson's financial interest in Gelsinger's trial,
specifically discussing the consent form at issue).
160.
See Smith & Byers, supra note 155, at 108 (recounting the investigation's
findings on the IRB); Wilson, supra note 158, at 306 (noting Gelsinger's unusual
ammonia levels).
161. See Smith & Byers, supra note 155, at 104-05.
162. See id. at 108-09.
163. See Mark Yarborough & Richard R. Sharp, Public Trust and Research a
Decade Later: What Have We Learned Since Gelsinger's Death?, 97 MOLECULAR
GENETIcS & METABOLISM 4, 4-5 (2009) (comparing Gelsinger's death with a more recent
patient's death and arguing that for the sake of public trust in science, disclosure and
accountability must be strengthened).
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64
Even so, the FDA
private organizations can still fund the research.1

would not approve any research or clinical application that would
modify the human genome, specifically germline editing, because its
long-term, unpredictable risks would not survive the FDA's rigorous
65
risk/benefit analysis.1
Overall, while the American system of regulating gene-editing

research is slow-moving because of the amount of bureaucratic
166
approval necessary to begin trials, it is not impossible to overcome.
The significant ambiguity in defining disease and disability illustrates
67
why the American process remains so slow.1 In light of the Gelsinger
tragedy, this slowness can be interpreted as deliberate caution unlikely
16 8
to change anytime soon.
Despite the government's hesitance, however, American scientists
continue to hold their place on the cutting edge of gene-editing
research-which acknowledges the fact that the American research
budget is the largest in the world, both due to public and private
funding.1 69 The American regulatory system seeks to exert tight
control over products pre-market, during the basic and clinical

research stages, but once the product is on the market, the American
system releases more control than most countries. 170 Once the product
gets on the market, doctors are permitted to use and prescribe the
product however they desire, which might not be for the same use that
the drug was approved.171
Interestingly, the American regulation of gene-editing research

does not involve the academic science community often-at most, their
members

might

serve

on

independent

review

boards,

funding

committees, and the FDA committees.17 2 Though it neglects learned
scientific societies to an extent, the American regulatory system
incorporates public engagement into its very framework, ensuring that
the public opinion on gene editing is honored throughout the process of

164.

See NAT'L ACADS. OF

SCIs., ENG'G, AND MED.,

supra note 8, at 184 (suggesting

that most jurisdictions prohibit germline modifications that do not have reproduction as
the end goal, but that existing research guidelines could be adapted to adequately
regulate this use).
165. See id. at 188-89.
166. See id. at 103-04, 171 (noting the regulatory process necessary for geneediting research).
167. See id. at 191.
168. See id. at 192 ("Regulatory agencies should not at this time authorize clinical
trials of somatic or germline genome editing for purposes other than treatment or
prevention of disease or disability."); Yarborough & Sharp, supra note 163, at 4-5
(arguing for more disclosure and accountability in order to salvage the American public's
trust in science).
See NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 109.
169.

170. See Charo, supra note 19, at 42.
171. See id. (nodding to the idea that once a drug is approved for the market in
America, it is permissible for off-label uses as well).
172. See id. at 41-42 (noting that the oversight of gene-editing technology falls
under the FDA's jurisdiction with no necessary checks from academic communities).
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regulating its research.1 73 Finally, the American legal framework
follows the recommendations of the International Summit on Human
Gene Editing in that it currently allows clinical applications of somatic
cell editing to progress, but functionally prohibits germline editing.1 7 4
2. The United Kingdom: Flexible but Strong Intervention

The UK regulates somatic cell research under the advanced
therapy medicinal products (ATMP) legal framework, which comes
from the European Union (EU).1 75 In order to get a somatic cell therapy
product on the market in the UK, both the European Medicines Agency

and the UK Medicines and Healthcare Products Regulatory Agency
must authorize the product's manufacturing.1 76 There are two ways

around the authorizations mentioned: the hospitals exemption and the
specials exemption. 177 The hospital exemption applies specifically to
ATMPs, but both exemptions approve a medicinal product that is
created for a specific patient.1 78
The British government has eagerly regulated gene therapy and

its evolving research since the 1980s.1 79 After the birth of the first IVF
baby, Louisa Brown, the government recognized a need for government
regulation in such a powerful scientific area and set up the Warnock
Committee to propose such regulation.1 80 Instead of building its

approach around a general prohibition on human embryo research and
fertility research, the Warnock Committee proposed a framework that
would allow flexibility, eventually through licensing under the Human
Fertilisation and Embryology (HFE) Act and the Human Fertilisation

and Embryology Authority (HFEA). 18 1 The Warnock Committee also
created and enacted the widely accepted fourteen-day limitation on

173. See id. at 40 (noting the regulatory public comment process). But see Martin
Gilens & Benjamin I. Page, Testing Theories of American Politics: Elites, Interest Groups,
and Average Citizens, 12 PERSP. ON POL. 564, 575-77 (2014) (suggesting that regulatory
capture by American elites and corporate interest groups exert much more influence over

the lawmaking process than the expressed policy preferences of average citizens). While
the American regulatory process aims to include public preference in the notice and
comment period, many scholars argue that the regulatory process has failed to do so
because it has been captured by corporate interest groups and affluent preferences.
174. See Baltimore, Baylis, Berg, Daley, Doudna, Lander, Lovell-Badge, Ossorio,
Pei, Thrasher, Winnacker & Zhou, supra note 5; Baltimore, Charo, Daley, Doudna, Kato,
Kim, Lovell-Badge, Merchant, Nath, Pei, Porteus, Skehel, Tam & Zhai, supra note 9.
175. Davies, supranote 28, at 15.
176. Id.
177. Id.
178. Id.
179. See Lovell-Badge, supra note 140, at 999 (producing a timeline showing
regulations since 1978).
180. See id. at 998; see also Hrouda, supra note 84, at 226-27 (arguing that Aldous
Huxley's fears about "the Fertilizing Room" were realized when Louisa Brown was born).

181.

See Lovell-Badge, supra note 140, at 998.
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research on human embryos that many countries adopted since
1984.182
The HFE Act of 1990 specified that the research using human
embryos must be necessary to one of the following enumerated
purposes: (1) promoting advances in the treatment of infertility, (2)

increasing the knowledge about the causes of miscarriages,

(3)

developing more effective techniques for contraception, and/or (4)

developing methods for detecting the presence of gene or chromosome
18 3
It also created the
abnormalities in embryos before implantation.
HFEA to review each proposed project for licensing under one of the
previously listed purposes. Additionally, the HFEA requires the

competence of the research team, the approval of an independent ethics
committee, the consent of the embryo donors for the specific
184
In
experiments, and the donors must have received counseling.
2001, three more purposes were added to the HFE Act: (1) increasing
knowledge about the development of embryos, (2) increasing
knowledge about serious disease, and (3) enabling any such knowledge
185
It also
to be applied in developing treatments for serious disease.
required that any human embryonic-stem cell line derived in the
186
Also
United Kingdom must be deposited in the UK Stem Cell Bank.

in 2001, Parliament quickly passed the Human Reproductive Cloning
Act, which prohibited the implantation of a human embryo created by
18 7
In 2004, the government
means other than fertilization in a woman.

included the removal, storage, and use of human tissue and organs in
the purview of the Human Tissue Authority under the Human Tissue
Act. 188
Under these laws, research conducted for reproductive purposes
could be licensed in the United Kingdom if it fulfills each of the criteria
needed, but heritable genome editing, for any purpose, is prohibited
completely.1 89 The contradiction here-that cells may be reconstructed

&

182. The fourteen-day rule prohibits the use of human embryos in research after
they are fourteen days old. See id. at 999; Shukla-Jones, Friedrichs & Winickoff, supra
note 141, at 25, 27-28 (comparing Japan and UK regulations on embryo research,
specifically noting their common 14-day rule). But see Insoo Hyun, Amy Wilkerson
Josephine Johnston, Embryology Policy: Revisit the 14-day Rule, 533 NATURE 169, 17071 (2016) (suggesting an extension to the globally-accepted 14-day rule because of
advancing technology that has allowed scientists to sustain embryos longer).
183. Lovell-Badge, supranote 140, at 1000.
184. See id. (describing HFEA functions); Human Fertilisation and Embryology
Act 1990, c. 37 § 8 (Eng.) (laying out the specific functions of the HFEA).
185. Lovell-Badge, supranote 140, at 1000.
186. Id.
187. See id. at 999-1000. See generally Human Reproductive Cloning Act 2001,
c. 23 (Eng.).
188. See generally Human Tissue Act 2004, c. 30 (Eng.).
189.

See NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 100; R. Isasi, E.

Kleiderman & B.M. Knoppers, Editing Policy to Fit the Genome? Framing Genome
Editing Policy Requires Setting Thresholds of Acceptability, 351 SCIENCE 337, 337-38
(2016).
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for reproductive research, but the germline must not be modified-

developed

because

of

advancing

technology

in

preventing

mitochondrial disease and Parliament's desire to make room for that

cure to develop. 190
Concerning the United Kingdom's recent exit from the EU, science
in the United Kingdom could look different in the near future.1 91 While

the United Kingdom and EU's hyper-governance of gene-editing
science does not differ dramatically, the flow of funding and ease of
collaboration with other EU countries might be a setback for science in
the United Kingdom.1 92 However, because of the skilled and
established scientists in the United Kingdom, private funding and
governmental restructuring could compensate for the lost funding.1 93
In addition, UK businesses and scientists could continue to comply
with EU laws in order to conduct business and research with other

countries.194
In comparison to the United States, the United Kingdom's eager
government regulation of gene-editing research is certainly extensive:
it maintains control over permissibility (i.e., the prohibition on
germline modification and the permissibility of research for
reproductive purposes) and over practical matters (i.e., type of cells
involved, activities done in the research, and purposes for which the

activities are done and the cells are used).1 95 However, both countries
use regulatory bodies for initial approval, an independent review board
for continued oversight, and patient consent as the three main pillars
of good gene-editing research.1 96 While the American regulations are
detailed and practical, the United Kingdom's regulations are driven by

idealistic goals.1 97 Where the United States releases much of the

190. See NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 102-03.
191. See Andrew H. Baker, Robin R. Ali & Adrian J. Thrasher, Impact of BREXIT
on UK Gene and Cell Therapy: The Need for Continued Pan-EuropeanCollaboration,27
HUM. GENE THERAPY 1, 1 (2016) (suggesting that science in the UK would be fine if
Brexit occurred, but it could be a setback for European science if collaboration is not
continued).

192.
193.

See id.
See id. at 2.

194.

NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 119.

195.

Id. at 105.

196.

Compare NAT'L AcADS. OF ScIs., ENG'G, AND MED., supra note 8, at 103-05,

171-72 (outlining the process of FDA approval of somatic cell gene editing clinical
testing, standard laboratory practices including consent, and IRB continued review of
ethics and safety), with Lovell-Badge, supra note 140, at 1000 (statutorily requiring
HFEA approval, donor consent, and independent ethics committee approval of geneediting technologies).
197.

Compare NAT'L ACADS. OF SCIS., ENG'G, AND MED., supra note 8, at 183-90

(examining the US's regulatory approach to germline and somatic cell research and
application, which evaluates one proposal at a time through a public rulemaking
process), and Charo, supra note 19 (arguing that detailed administrative rules can be
more responsive than legislation), with Lovell-Badge, supra note 140, at 1000 (describing
the HFE Act centering around guiding purposes and promulgating more specific
legislation from it).
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control over medicinal products once they are on the market, the
United Kingdom retains a strong hand in regulating products and their

uses even in the market.1 98 The Nuffield Council on Bioethics credits
the United Kingdom's success in widespread compliance with the
HFEA to the fact that real practitioners involved in learned societies
had a hand in creating the regulations.1 99 Finally, the United Kingdom
incorporates public opinion by outsourcing interactive activities to
independent and nongovernmental agencies instead of infusing public
200
opinion into the rulemaking process, like the United States does.
While the United Kingdom's positions might remain more consistent

because its laws are not directly dependent on public feedback, 2 0 ' it
might be more efficient to have a centralized organization like the
government incorporate both law and public opinion, as in the United

States.2 0 2 Either way, scholars have continually emphasized the
importance

of public

engagement

when

it comes

to

scientific

regulations because of its universal effects on humanity.2 0 3
3. Japan: Flourishing under Regulatory Reluctance
Japan's relationship with general bioethics is different than the
United States and the United Kingdom because it incorporates

academic societies in a more potent capacity. 204 At first, Western ideas
about bioethics strongly influenced Japanese academia via newly
translated literature. 205 In response, as early as the 1970s, the
Japanese government began to adopt policies concerning informed

consent of patients, brain death, and quality of life. 206 As scientific
research began to expand, the government selected a committee to
promulgate
involvement,
public
with
and,
regularly
meet
207
The committee
administrative guidelines for scientific research.

See Charo, supra note 19.
NUFFIELD COUNCIL ON BIOETHICS, supra note 84, at 106.
See NAT'L ACADS. OF ScIS., ENG'G, AND MED., supra note 8, at 175.
200.
See Charo, supra note 19 (noting that legislation for biotechnology is
201.
generally more politically credible as well).
NAT'L ACADs. OF SCIs., ENG'G, AND MED., supra note 8, at 175; see Charo,
202.
supra note 19 (pointing out that regulations can be more responsive to the public than
the "blunt instrument" of legislation).
198.
199.

203.

See NAT'L ACADS. OF SCIs., ENG'G, AND MED., supra note 8, at 163-64.

204. See Akira Akabayashi, Bioethics in Japan, 1980-2009: Importation,
Development, and the Future, 1 ASIAN BIOETHICS R. 267, 268 (2009) (arguing that
Japanese bioethics began with the academic debate over brain death and organ
transplant in the 1980s, and was finally resolved by law as a prophylactic reaction to the
academic, public, and political debate that lasted over two decades).
205. See id. at 267.
206. See id. at 268-69 (explaining the Japanese concern for bioethics through the
"Tokai University Euthanasia Judgment," where a scientist was sentenced to two years
in prison for administering potassium chloride to a terminally ill patient).
207. See id. at 270-71 (describing what the author deems to be Phase II of the
Development of Japanese research ethics).
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incorporated a public comment system later, which allowed for the
public to engage in policymaking in an organized, efficient way. 208 Due
to these regulations, ethics committees in scientific institutions

became ubiquitous and started catching scientific fabrications and
misconduct more often.20 9 Governmental and academic institutions
created internal offices for a new whistle-blower reporting system in

order to address conflicts of interest or other unethical research. 210 In
2004, the Cabinet Office Council for Science and Technology Policy's
Expert Panel on Bioethics published a report called the "Fundamental
Policy on Handling of Human Embryos," which explained that the
government viewed human embryos as "sprouts of human life" that
could be used in scientific research with the proper honor and
respect. 211 As institutions began to actually conduct genomic research,
they required stringent protection of patients' personal information

and provided genetic counseling throughout the process, according to
the Ethical Guidelines for Human Genome and Gene Analysis
2 12
Research, one of the most rigorous research guidelines in the world.
Unfortunately, while bioethics has certainly flourished in Japan, the
medical system has suffered from a dramatic decline in doctors and

funding

recently because

of heightened

premiums

for health

insurance.2 1 3
Specifically, Japan's government commissioned a panel of experts
from scientific fields to create new guidelines for gene-editing
research. 214 In doing so, the expert panel held multiple public
engagement sessions with its own citizens and other countries in order

to understand the issues from many perspectives. 215 Japanese
regulations of human embryo research built on Japan's 2004 policy,
which disallowed the creation of human embryos for research unless it
met each of four criteria: (1) scientific significance in life science and

medicine cannot be obtained other than through the use of human
embryos, (2) the benefits or anticipated benefits are socially
appropriate, (3) there is assurance of human safety, and (4) safeguards

208.

See id. (describing what the author deems to be Phase II of the Development

of Japanese research ethics).

See id. at 271 (describing what the author deems to be Phase II of the
209.
Development of Japanese research ethics); see, e.g., David Swinbanks, Gene Therapy
Gets Double Dose of Screening, 367 NATURE 399, 399 (1994) (discussing the
establishment and function of ethics committees in response to 1993 legislation in both
the Moriyama and Niigata Universities).
210.
See Akabayashi, supra note 204, at 271 (describing what the author deems
to be Phase II of the Development of Japanese research ethics); see also, e.g., Swinbanks,
supra note 209.
See Akabayashi, supra note 204, at 272.
211.
212.
See id. at 273.
213.
See id. at 274.
214.
See Shukla-Jones, Friedrichs, & Winickoff, supra note 141, at 22 (recounting
a presentation on public engagement in Japan from two Cabinet Office members).
215.
See id. at 22, 27-28.

1756

VANDERBILTJOURNAL OFTRANSNATIONAL LAW

[voL. 53:1727

are placed to avoid raising concerns of reducing human beings to tools
or means. 216 The panel's recommendations prohibited germline editing
in clinical research, but encouraged research into better understanding
21 7
It allowed
the function of genetics at an early developmental stage.

the use of surplus embryos for research, limited the handling period of
human embryos for research to fourteen days, and required secure
218
disposal of human embryos used in research.
But Japan's inclusive and innovative regulations were not the
government's first response to the growth of gene-editing

technology. 2 19 After the Panel presented the aforementioned report in
2016, confusion broke out. The Panel itself did not have the power to
create, implement, and enforce guidelines based on its findings, and

had charged the relevant academic societies with the responsibility of
self-regulation accordingly. 220 The academic societies pushed back,
arguing that the government should pay for and create regulations for
the scientific community. 22 1 As the relationship between the Panel and
the academic societies began to dissolve, Chief Cabinet Secretary Suga
declared that the "Japanese government must become responsibly
involved in genome-editing technology." 222 From this statement came
the expert panel and interim report, both of which scholars consider
223
vague and unenforceable.

Where the United States tests the same drug more than once
before approval, Japanese regulations make a single initial evaluation
of a drug's risk that categorizes it into a higher or lower level of

oversight based on the dangers of its risks. 224 Further, what is
interesting about Japan's production of gene-editing regulation is that
225
The
it works best as a reactive measure-from the bottom up.
Japanese government only took an interest in scientific regulations
after the Japanese public pushed back against physician-assisted

suicide. 2 26

216. Id. at 27-28.
217. See id.
218. See id.
219. See Eisuke Nakazawa, Keiichiro Yamamoto, Aru Akabayashi & Akira
Akabayashi, Regulations on Genome Editing of Human Embryos in Japan: Our Moral
Moratorium, 27 CAMBRIDGE

Q.

HEALTHCARE ETHICS 360, 362 (2018).

220. Id.
221. See id.
222. Id.
Id. at 263. See also Heidi Ledford, The Landscape for Human Genome
223.
Editing: A View of InternationalRegulations Suggests Where in the World a CRISPR
Baby Could Be Born, 526 NATURE 310, 310-11 (2015) (suggesting that Japan's guidelines
fall into the same unenforceable category as China's).
224. See Charo, supra note 19.
225. See Nakazawa, Yamamoto, Akabayashi & Akabayashi, supra note 219; see
also Akabayashi, supra note 204, at 270 (describing Japan's choice to regulate bioethical
policy decisions through administrative guidelines crafted substantially from public
response at committee meetings).
226. See Akabayashi, supranote 204, at 269-70.

20201

1757

REGULA TING CRISPR TRANSNA TIONALLY

Where the United Kingdom and the United States have both
regulated scientific protocol from top down, or from the government to

the scientific professional community, to the public consumers, Japan
has taken the opposite approach in waiting for the public to request
the government's intervention before it gets involved in scientific
developments. 227 All three countries incorporate the public's opinions,
value governmental transparency and patient consent, and intervene

significantly in the scientific research process. 228 Each of the countries
incorporate these values into a system that promotes ethical scientific
advancement, yet the United States emphasizes deliberate progress
through its extensive, 22 9 detailed regulatory process for funding; the

'

United Kingdom legislates based on unifying, broad ideals; 230 and
Japan regulates according to the needs of academic societies. 23

VI. THE INTERNATIONAL GENE-EDITING ETHICS COMMISSION

Gene editing of both somatic and germline cells affects biological
science globally and is growing more quickly than governments can
manage. 23 2 Considering some countries are already using somatic cell
editing in clinical research and germline editing could follow closely
behind, realistic and effective regulation of gene-editing research has
never been more crucial. 233 Soft-law agreements that express broad

227. Compare NAT'L AcADS. OF SCIS., ENG'G, AND MED., supra note 8, at 103-05,
171-72 (outlining the process of FDA approval of somatic cell gene editing clinical
testing, standard laboratory practices including consent, and IRB continued review of
ethics and safety), with Lovell-Badge, supra note 140, at 1000 (statutorily requiring
HFEA approval, donor consent, and independent ethics committee approval of gene-

editing technologies), and Shukla-Jones, Friedrichs, & Winickoff, supra note 141, at 22,
27-28 (explaining that a Japanese Cabinet Officer's example of public engagement
sessions illustrates the prioritization of public opinion in Japanese scientific regulation).
228.
Compare NAT'L AcADS. OF SCIs., ENG'G, AND MED., supra note 8, at 103-05,
171-72 (outlining the process of FDA approval of somatic cell gene editing clinical
testing, standard laboratory practices including consent, and IRB continued review of

ethics and safety), with Lovell-Badge, supra note 140, at 1000 (statutorily requiring
HFEA approval, donor consent, and independent ethics committee approval of geneediting technologies), and Shukla-Jones, Friedrichs & Winickoff, supra note 141, at 22,
27-28 (giving a Cabinet Office member offering Japan's panel and public engagement
sessions as an example of inclusive regulation).
229. See NAT'L AcADS. OF ScIS., ENG'G, AND MED., supra note 8, at 103-05, 17172.
230. See Lovell-Badge, supra note 140, at 1000-01.
231. See Shukla-Jones, Friedrichs & Winickoff, supra note 141, at 22, 27-28.
232.
See NAT'L AcADS. OF SCIs., ENG'G, AND MED., supra note 8, at 57 ("As noted
by former FDA Commissioner Robert Califf, '[s]cientific advances do not adhere to
national boundaries and therefore it is critical that we understand the evolving views of
our international counterparts.'").
233.
See Shukla-Jones, Friedrichs & Winickoff, supranote 141, at 38 (stating that
because human applications are a reality for gene editing now, countries must
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principles about the human genome, though noble and integral to
biosafety of humankind, have failed to properly motivate scientists to
beliefs about genome editing. 234
comply with transnational
Additionally, differing regulations among different countries lead to
confusion at best, and inaction at worst. 235

In response, this Note proposes to form The International GeneEditing Ethics Commission (Commission), an entity made up of
236
democratically elected representatives of participating countries.

This Commission is distinct from other international committees, such
as The International Summit on Human Gene Editing, because it
harnesses the power of scientific publication to incentivize scientists
237
across the globe to become members bound by its ethical guidelines.
The Commission would compile a valuable database of gene-editing

data that is available only to member countries, evaluate research
proposals, promulgate mandatory ethical standards, and provide
significant funding to those research proposals that commit to undergo

&

distinguish between somatic, with which most countries are comfortable, and germline
editing, with which most countries are not comfortable and create regulations for both
kinds).
234. See, e.g., Andorno, supra note 90, at 134 (noting that important scientific
communities like the United Kingdom, Germany, and France rejected even the most
binding international treaty, the Oviedo Convention); Hannum, supra note 92, at 32223.
235. See Melillo, supra note 16, at 771 (emphasizing the need for global consensus
concerning the regulation of gene editing); Preetika Rana, How a Chinese Scientist Broke
the Rules to Create the First Gene-Edited Babies, WALL ST. J. (May 10, 2019), https:
//www.wsj.com/articles/how-a-chinese-scientist-broke-the-rules-to-create-the-first-geneedited-babies-11557506697?mod=wsj_vanderbilt3 [https://perma.cc/ZH9Z-2VPJ] (archived Aug. 31, 2020) (outlining Dr. He's communications with other scientists about his
CRISPR clinical applications, which mostly consisted of scientists urging caution and
attempting to create a deliberate ignorance about his experiment).
236. See Shukla-Jones, Friedrichs & Winickoff, supra note 141, at 30
(summarizing experts' opinions about the benefits and dangers of international
harmonization of gene-editing technology regulation, most of whom agreed that
harmonization is worth trying); see also Charo, supra note 19. This Commission would
aim for the successful and influential impact of the Council for International
Organizations of Medical Sciences, which creates global standards for human subjects,
but it would differ because it specifically addresses gene-editing research and clinical
applications rather than medical science as a whole. "Democratically elected
representatives" may look different for different countries. For instance, in the United
States, it is most likely that the President would have to appoint the US representatives
to this Commission in order to comply with the US Constitution. Importantly, though,
since the President is elected by the American public, these appointments are, at least
partially, democratic. My hope is that these representatives would be democratically
elected through the available processes in each participating country.
See NAT'L ACADS. OF SCIS., ENG'G, AND MED., supra note 8; Baltimore, Charo,
237.
Daley, Doudna, Kato, Kim, Lovell-Badge, Merchant, Nath, Pei, Porteus, Skehel, Tam
Zhai, supra note 9 (discussing how the International Summit on Human Gene Editing
offers little incentive to member nations other than publicly available expert findings
and its ethical guidelines are not binding on any nation); see also Charo, supra note 19
(stating that the Council for International Organizations of Medical Sciences creates
global standards for human subjects).
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regular reviews by the commission as well as the reviews required by
their own countries. Most importantly, the Commission would create
and enforce a clear whistle-blower framework to allow scientists to

handle a future situation like that with Dr. He more effectively. In
order to become a member nation, the country must demonstrate its
commitment to transparency, responsible science, and promoting wellbeing of the entire human race, as well as of individuals.
The International Gene-Editing Ethics Commission has four main

features: (1) a database, (2) research funding, (3) a proposal evaluation
system, and (4) mandatory ethical standards. The database and the
research funding serve as incentives to join the Commission, in an

effort to promote the ethical advancements of gene-editing technology.
A. The Incentives: Information and Funding
Moving forward, the scientific community must be adequately

incentivized to faithfully comply with globally established regulations
in research, both basic and clinical. In his article reflecting on Jesse
Gelsinger's death, Dr. Wilson noted that
It should be recognized . . . that academic medicine is a competitive profession
with the primary measure of success being recognition by your colleagues of your
research accomplishments. This recognition is critical to sustaining one's
research agenda through the successful competition for grants and the awarding
of academic promotions and tenure.

238

Given the powerful motivator of publication for medical researchers;

academic societies and journals hold influential power over the global
scientific community. 239 Japan's struggle between academic societies
and governmental regulation also points to a need for a body outside of
academia and government to order the incentives of the community
correctly. 2 40 To ensure ratification in scientifically-influential nations
like the United Kingdom, 24 1 membership in the Commission must be
extremely valuable so that countries are incentivized to join. These
incentives must also be valuable in order to incentivize international,

238. James M. Wilson, Lessons Learned from the Gene Therapy Trial for
Ornithine Transcarbamylase Deficiency, 96 MOLECULAR GENETICS & METABOLISM 151,
(2009)
155
https://reader.elsevier.com/reader/sd/pii/S 109671920800499X?token=lE4DB222E5BOl
B2440CF54697F343D7F8F53168665D71003D45002A7606CCA261B513232DB88733D
1CDE4E2686D036B3 [https://perma.cc/WEC3-G652 (archived Aug. 31, 2020).
239. See infra Part III.B.3 (discussing Japan's journey to regulation of geneediting technology).
240. See id.; Shukla-Jones, Friedrichs, & Winickoff, supra note 141, at 22 (using
a Cabinet Office member offering Japan's panel and public engagement sessions as an
example of inclusive regulation).
241. Andorno, supra note 90, at 134 (noting the United Kingdom did not adopt the
Convention because it was too restrictive, Germany refused because it was too
permissive, and France refused because of its own simultaneous bioethics law reform).
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specific regulations-an accomplishment not yet achieved by other
international agreements. Ideally, the Commission would utilize the
influence of the major peer-reviewed, scientific journals by favoring

scientists' papers from member countries. Though this perk would
likely require substantial funding on the front end and scientists might

resent the favoritism, the scientific community's concern for safe,
ethical research would help motivate funding from universities and
nations around the world.

B. The Purpose:Ethical Advancement of Gene Editing
While one important function of the Commission would be to
provide an efficient epicenter for scientists to share their findings and
help each other advance across borders, its most crucial function would
be the accountability created among its members through the
promulgation of ethical standards for gene-editing research and a
whistle-blower framework to enforce these standards. Had this been
available to many scientists who heard about Dr. He's research before
he went forward with his clinical application, there is a possibility that
he could have been prevented from altering the human genome
242
Dr. He's clinical application
permanently and without permission.
of CRISPR had many negative consequences, among which are the lack

of consent from the human population before permanently altering the
human genome. Without understanding the effect of genome editing or
its ramifications throughout future generations, this unapproved
experiment changed the human genome as we knew it.

The Commission's standards would be created by those appointed
to the Commission, with each member country appointing two citizens
to represent them in the Commission. The Commission would meet to

propose and discuss ideas for ethical standards and submit the finished
product to the public for approval. Learning from the Japanese and

24 3
the
American approaches that emphasize public engagement,
Commission would create a public notice and comment period, similar
to the American procedures laid out in the Administrative Procedure

Act, 244 before enacting new regulations. Adding a check on the

242. See Cyranoski, supra note 1 (discussing the scientists who knew about He's
clinical research before it actually happened and whether they should have done more
to prevent it).
243. Shukla-Jones, Friedrichs & Winickoff, supra note 141, at 22, 27-28; see
Charo, supra note 19 (noting that the oversight of gene-editing technology falls under
the FDA's jurisdiction).
244. Administrative Procedure Act, 5 U.S.C. §§ 551-59 (2018) (outlining the
process of producing administrative regulations through notice and comment
rulemaking, which includes public engagement). See also Gilens & Page, supra note 173.
I would like to note that the American regulatory process is not a perfect solution because
of the regulatory capture problem discussed previously. I would suggest regulating this
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Commission through the public helps avoid a future situation like the
one with Dr. He-the pace of the use of gene-editing technology on
humans could then match with the public's preference. 245 Dr. He's
modification of germline editing came before much of the world
assented to germline editing. Had his project been subject to regulation
created based on public opinion, then, it would have been prohibited.
Additionally, public engagement in the use of science also breaks any
aristocratic barriers created by elite scientific academia and
encourages public trust in the scientific community. 246 Finally, because

humanity as a whole will be affected by the use of germline editing,
incorporating public opinion into the regulatory process ensures that

the rules reflect the will of the people.
Specifically, the Commission could solicit public opinions from
many different countries through online polls and surveys in order to
gauge and quantify the public sentiment towards new technology and
its applications. Realistically, it would be important to break this down

into a short explanation of the technology and then ask whether the
survey-taker would be comfortable with the technology (1) being used
in basic research and (2) being used on a family member in a clinical
trial. That way, the Commission can combat potential cognitive
barriers by making people think about use on a loved one, instead of a

faceless test subject. Once the public approves the standards, member
countries would be informed of them and held to them.
The Commission would enforce the publicly-enacted standards
24 7
through a whistle-blower system for the scientific community.

Taking a page out of the International Summit on Human Gene
Editing's book, self-regulation among scientists seems to be a more
effective way to enforce scientific protocol transnationally than
through a broader treaty like the UNESCO Declaration, or even the

Oviedo Convention, that allows countries to create laws based on its
broad principles. This framework would provide a system for scientists
who are concerned by experiments or research that threaten one of the
fundamental principles of the Commission to anonymously report their
concern to the Commission, who will then investigate the issue and
impose sanctions if necessary.

notice and comment period in such a way that corporate interest groups and elite voices
are not so controlling. Perhaps there could be a spending limit for lobbying these
preferences to the Committee that equalizes the playing field, for example.
245. See Cyranoski, supranote 1.
246. See generally Christi J. Guerrini, G. Evan Spencer & Patricia J. Zettler, DIY
CRISPR, 97 N.C. L. REV. 1399 (2019) (discussing the dangers of the growing use of
CRISPR by nonscientists in the US).
247. Arthur Kantrowitz, Elitism vs. Checks and Balances in Communicating
Scientific Information to the Public, 4 HEALTH SAFETY & ENV'T. 101, 103, 107-08 (1993)
(advocating an extension of the scientific community's traditional self-policing nature in
order to hold scientists accountable for their publicly-expressed policy preferences
instead of relying on their credentials and prestige alone).
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The Commission only has its own internal power and authority to

penalize members who violated the guidelines. Possible sanctions
could include monetary penalties to the relevant institution, which
would incentivize the institution as a whole to monitor its researchers

closely. Privileges of membership (funding and database access) could
also be suspended as a penalty for violating guidelines. As a last resort
for serious offenses, an institution's, or even a country's, membership
could be suspended or revoked.

The International Commission would encourage the already
strong sense of communication among the participating scientific
communities such that it benefits all scientists involved through

helpful databases, workshops, and collaborations. While this would
benefit scientific advancement generally, it would also encourage
transparency among peers. 248 The whistle-blower framework would
allow peers to warn the Commission if a peer overstepped an ethical
line through an anonymously written form. Anonymity would allow the
whistle blower to avoid any stigmatization that might come with
reporting a peer's infraction, but the writing ensures that the whistle

blower has taken time to articulate the problems with the peer's
experiment.

C.

Practicality

This Commission is not a panacea for the regulation of advancing
biotechnology. In particular, this solution relies on the assumption that
many nations will be able to come to agreement on a code of ethics for
scientific technology as it evolves further. Given how differently the

United States, the United Kingdom, and Japan have regulated
technology nationally, agreement might only be achieved through
broad language, which this Note has already argued as ineffective.
However, given the Committee's strong incentive for membership and
harnessing of academia, this solution provides a different, more viable
approach to international regulation.
Additionally, the practicality of obtaining scientific journals'
agreement to favor member nations' work could be a hurdle to this
solution's success for several reasons. First, scientific journals seek to
publish work based on its merits, and less on who wrote it. Scientists
themselves might push back against the Commission since their
careers depend on their country's membership, over which they have
little control. Second, it could further divide the public from academia.

But it could also cause biotechnology to become politicized to an
248.
underproductive extent. See Shukla-Jones, Friedrichs & Winickoff, supra note 141, at 3,
28-30 (presenting global experts' hesitations on international governance of gene-editing
technologies, including politicization and forcing countries to accept values of another
country in terms of bioethics, but citing that a flexible framework could cure these
issues).
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In a similar vein, whether or not regulation can ever accurately capture

public opinion, especially on a scale as large as proposed here, remains
an issue for this Committee's rulemaking procedures.2 49 Even given
these concerns, this solution provides a middle ground between vague
international agreements and specific, binding agreements. Vague
international agreements gain universal adoption, but varying kinds
of implementation. Specific, binding agreements gain less support, but
more uniform implementation. This solution provides a way to gain

wide acceptance to the broad goal of the Commission, but specific,
uniform adherence to the specific guidelines developed by participating
countries.

V. CONCLUSION

Despite the scientific community's best efforts to restrain
advancing technology to allow for international ethical standards to
catch up, Dr. He's experiment exemplifies that science can be hard to
control. Specifically, gene editing has been at the forefront of human
thought since we have existed-through the most primal selection of

sexual mates, to Mendel's pea plants, to Nazism, to assisted
reproductive technology, to CRISPR itself.25 0 Through that lens, Dr.
He's jumping into germline editing without international approval
should not be so surprising. The international scientific community

began a conversation about this issue, and countries attempted to
regulate this issue independently, but those two forces must unite in
finding a way forward. By streamlining the scientific community's
expertise and already existing lines of communication via peer-review
and the internet to trigger a quick legal response in the appropriate
country, the International Gene-Editing Ethics Commission will allow
scientists to use technologies like CRISPR safely across the globe. The
question is no longer whether to edit the human genome, but how to do

so ethically and safely.
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249. See Gilens & Page, supra note 173.
250.
See infra Part II.A (discussing how historical eugenic thought serves as a
warning sign to regulate CRISPR internationally).
*
J.D. Candidate, Vanderbilt Law School, 2020. I would like to thank Dr. Ellen
Clayton for her advice during the writing process, the Vanderbilt Journal of
Transnational Law for their constructive and meticulous work throughout the editing
process, and my fiance Austin Chapman for cultivating my love of bioethics.

***

